





**Supplementary Figure 1.** Cumulative liver-related events by (A) NAFLD-FS category ( $P < .001$ ); (B) APRI category ( $P < .001$ ); (C) FIB-4 score category ( $P < .001$ ); and (D) BARD score category ( $P < .001$ ).



**Supplementary Figure 2.** Cumulative death/liver transplantation by (A) NAFLD-FS category ( $P < .001$ ); (B) APRI category ( $P < .001$ ); (C) FIB-4 score category ( $P = .03$ ); and (D) BARD score category ( $P = .001$ ).

**Supplementary Table 1.** Multivariate aHRs and 95% CIs of Outcome by Risk Score Category for the Outcome of Liver-Related Events

	HR	95% CI	P value
<b>Model 1</b>			
NAFLD-FS			
Low risk	1 (Ref)		
Intermediate risk	7.7	1.4–42.7	<.02
High risk	34.2	6.5–180.9	<.001
Sex			
Female	1 (Ref)		
Male	1.0	0.5–1.9	.9
Race category			
White	1 (Ref)		
Non-white	2.1	0.5–9.4	.3
Hypertension			
No	1 (Ref)		
Yes	0.7	0.4–1.3	.3
Statins			
No	1 (Ref)	0.4–3.1	.8
Yes	1.1		
Fibrosis stage			
0	1 (Ref)	0.05–2.4	.3
1–2	0.3	0.6–10.3	.2
3–4	2.6		
<b>Model 2</b>			
APRI			
Low risk	1 (Ref)		
Intermediate risk	8.8	1.1–67.3	.04
High risk	20.9	2.6–165.3	.004
Sex			
Female	1 (Ref)		
Male	1.6	0.8–3.4	.2
Age	1.1	1.04–1.13	<.001
BMI	1.0	0.9–1.1	.4
Race category			
White	1 (Ref)		
Non-white	1.3	0.3–6.4	.7
Hypertension			
No	1 (Ref)		
Yes	0.7	0.4–1.4	.3
Statins			
No	1 (Ref)		
Yes	0.9	0.3–2.3	.8
Diabetes			
No	1 (Ref)		
Yes	0.8	0.4–1.6	.6
Fibrosis stage			
0	1 (Ref)		
1–2	0.3	0.05–2.0	.2
3–4	3.4	0.9–14.4	.07
<b>Model 3</b>			
FIB-4			
Low risk	1 (Ref)		
Intermediate risk	0.92	0.2–4.8	.9
High risk	14.6	4.1–52.6	<.001
Sex			
Female	1 (Ref)		
Male	1.1	0.5–2.1	.9
Race category			
White	1 (Ref)		
Non-white	0.95	0.2–4.8	.9
BMI	1.0	0.9–1.1	.7
Hypertension			
No	1 (Ref)		
Yes	0.7	0.4–1.3	.2

**Supplementary Table 1.** Continued

	HR	95% CI	P value
Statins			
No	1 (Ref)		
Yes	1.1	0.4–2.8	.9
Diabetes			
No	1 (Ref)		
Yes	0.7	0.3–1.3	.2
Fibrosis stage			
0	1 (Ref)		
1–2	0.6	0.1–4.0	.6
3–4	6.2	1.6–23.6	.007
<b>Model 4</b>			
BARD			
Low risk	1 (Ref)		
Intermediate risk	6.2	1.4–27.2	<.02
High risk	6.6	1.4–31.1	<.02
Sex			
Female	1 (Ref)		
Male	1.7	0.8–3.5	.1
Age	1.1	1.04–1.1	<.001
Race category			
White	1 (Ref)		
Non-white	1.5	0.3–6.7	.6
Hypertension			
No	1 (Ref)		
Yes	0.6	0.3–1.2	.2
Statins			
No	1 (Ref)		
Yes	0.5	0.2–1.3	.2
Fibrosis stage			
0	1 (Ref)		
1–2	0.4	0.07–2.6	.4
3–4	5.3	1.5–18.7	<.001

**Supplementary Table 2.** Multivariate aHRs and 95% CIs of Outcome by Risk Score Category for the Outcome of Death/Liver Transplantation

	HR	95% CI	P value
<b>Model 1</b>			
NAFLD-FS			
Low risk	1 (Ref)		
Intermediate risk	4.2	1.3–13.8	<.02
High risk	9.8	2.7–35.3	<.001
Sex			
Female	1 (Ref)		
Male	0.7	0.3–1.5	.4
Race category			
White	1 (Ref)		
Non-white	1.8	0.4–8.2	.4
Hypertension			
No	1 (Ref)		
Yes	1.6	0.8–3.1	.2
Statins			
No	1 (Ref)		
Yes	1.2	0.3–4.4	.8
Fibrosis stage			
0	1 (Ref)		
1-2	0.7	0.2–2.5	.6
3-4	2.0	0.7–6.4	.2
<b>Model 2</b>			
APRI			
Low risk	1 (Ref)		
Intermediate risk	1.1	0.4–2.7	.9
High risk	3.1	1.1–8.4	.03
Sex			
Female	1 (Ref)		
Male	1.1	0.5–2.3	.9
Age	1.1	1.05–1.14	<.001
BMI	1.0	0.9–1.1	.9
Race category			
White	1 (Ref)		
Non-white	2.5	0.5–12.6	.3
Hypertension			
No	1 (Ref)		
Yes	1.4	0.7–2.6	.4
Statins			
No	1 (Ref)		
Yes	0.9	0.3–3.3	.9
Diabetes			
No	1 (Ref)		
Yes	0.8	0.4–1.7	.6
Fibrosis stage			
0	1 (Ref)		
1-2	0.7	0.2–2.3	.6
3-4	2.6	0.8–8.7	.1
<b>Model 3</b>			
FIB-4			
Low risk	1 (Ref)		
Intermediate risk	2.3	0.8–6.6	.1
High risk	6.9	2.3–20.4	.001
Sex			
Female	1 (Ref)		
Male	0.6	0.3–1.4	.3
Race category			
White	1 (Ref)		
Non-white	0.9	0.2–4.3	.8
BMI	1.0	0.9–1.04	.3
Hypertension			
No	1 (Ref)		
Yes	1.4	0.7–2.7	.3

**Supplementary Table 2.** Continued

	HR	95% CI	P value
Statins			
No	1 (Ref)		
Yes	0.8	0.2–2.9	.8
Diabetes			
No	1 (Ref)		
Yes	0.8	0.4–1.6	.6
Fibrosis stage			
0	1 (Ref)		
1–2	1.1	0.4–3.5	.8
3–4	3.3	1.1–10.1	.03
<b>Model 4</b>			
BARD			
Low risk	1 (Ref)		
Intermediate risk	1.8	0.6–5.1	.3
High risk	1.6	0.5–4.9	.4
Sex			
Female	1 (Ref)		
Male	1.1	0.5–2.4	.8
Age	1.1	1.05–1.13	<.001
Race category			
White	1 (Ref)		
Non-white	0.5	0.1–4.2	.6
Hypertension			
No	1 (Ref)		
Yes	1.2	0.6–2.4	.5
Statins			
No	1 (Ref)		
Yes	0.5	0.2–2.4	.5
Fibrosis stage			
0	1 (Ref)		
1–2	0.9	0.3–2.6	.8
3–4	3.4	1.2–9.7	.02